In Silico, In Vitro, and Pharmacokinetic Studies of UBMC-4, a Potential Novel Compound for Treating against <i>Trypanosoma cruzi</i>
The lack of therapeutic alternatives for the treatment of Chagas disease, a neglected disease, drives the discovery of new drugs with trypanocidal activity. Consequently, we conducted in vitro studies using UBMC-4, a potential <i>Trypanosoma cruzi</i> AKT-like pleckstrin homology (PH) do...
Main Authors: | Christian Bustamante, Andrés Felipe Díez-Mejía, Natalia Arbeláez, Maurilio José Soares, Sara M. Robledo, Rodrigo Ochoa, Rubén E. Varela-M., Marcel Marín-Villa |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Pathogens |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-0817/11/6/616 |
Similar Items
-
In Vitro Evaluation of Arylsulfonamide Derivatives against <i>Trypanosoma cruzi</i>
by: Policarpo Ademar Sales Junior, et al.
Published: (2023-06-01) -
Reaching for the Holy Grail: insights from infection/cure models on the prospects for vaccines for Trypanosoma cruzi infection
by: Juan Bustamante, et al.
Published: (2015-05-01) -
Chagas Disease: Detection of <i>Trypanosoma cruzi</i> by a New, High-Specific Real Time PCR
by: Simone Kann, et al.
Published: (2020-05-01) -
Paracrine Signaling Mediated by the Cytosolic Tryparedoxin Peroxidase of <i>Trypanosoma cruzi</i>
by: María Laura Chiribao, et al.
Published: (2024-01-01) -
Identification of <i>Trypanosoma cruzi</i> Growth Inhibitors with Activity In Vivo within a Collection of Licensed Drugs
by: Nieves Martinez-Peinado, et al.
Published: (2021-02-01)